Health Care & Life Sciences » Pharmaceuticals | Rexahn Pharmaceuticals Inc.

Rexahn Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
37.10
28.30
27.50
32.90
42.40
Gross Income
37.10
28.30
27.50
32.90
42.40
SG&A Expense
7,941.70
13,240.90
18,235.90
16,380.50
17,312.40
EBIT
7,978.80
13,269.20
18,263.40
16,413.40
17,354.70
Unusual Expense
1,365.70
5,180.10
3,986.70
7,300.60
7,594.20
Non Operating Income/Expense
204.20
206.20
211.10
-
552.60
Interest Expense
-
-
-
313.10
-
Pretax Income
9,499.40
18,521.60
14,384.60
9,307.30
25,294.50
Consolidated Net Income
9,499.40
18,521.60
14,384.60
9,307.30
25,294.50
Net Income
9,499.40
18,521.60
14,384.60
9,307.30
25,294.50
Net Income After Extraordinaries
9,499.40
18,521.60
14,384.60
9,307.30
25,294.50
Net Income Available to Common
9,499.40
18,521.60
14,384.60
9,307.30
25,294.50
EPS (Basic)
0.74
1.05
0.80
0.40
0.92
Basic Shares Outstanding
12,864.90
17,610.70
18,238.80
21,744.70
27,390.50
EPS (Diluted)
0.74
1.05
0.79
0.43
0.92
Diluted Shares Outstanding
12,864.90
17,610.70
18,238.80
21,744.70
27,390.50
EBITDA
7,941.70
13,240.90
18,235.90
16,380.50
17,312.40
Non-Operating Interest Income
49.30
133.90
103.30
118.60
207.00

About Rexahn Pharmaceuticals

View Profile
Address
15245 Shady Grove Road
Rockville Maryland 20850
United States
Employees -
Website http://www.rexahn.com
Updated 09/14/2018
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; RX-5902 or Supinoxin for metastatic triple negative breast cancer; and RX-0201 or Archexin for renal cell carcinoma, glioblastoma, ovarian, stomach, and pancreatic cancer. It also develops nano-based drug delivery systems.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.